Ergoteles LLC Allogene Therapeutics, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $75,366 - $136,504	11,116 Added 16.96%	76,675 $874,000
Q1 2022 May 13, 2022	SELL	$7.65 - $15.29 $39,221 - $78,391	-5,127 Reduced 7.25%	65,559 $597,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $265,265 - $495,377	20,203 Added 40.02%	70,686 $1.06 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $1.06 Million - $1.4 Million	50,483 New	50,483 $1.3 Million
Q2 2021 Aug 12, 2021	SELL	$23.49 - $35.8 $1.74 Million - $2.66 Million	-74,276 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$25.79 - $39.02 $1.92 Million - $2.9 Million	74,276 New	74,276 $2.62 Million

174

139M

75.8K

52.8K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $293M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.